Cite
HARVARD Citation
Kato, K. et al. (2019). Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet oncology. 20 (11), pp. 1506-1517. [Online].